Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…

Continue Reading Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Alkermes’ Alixorexton Shows Promise in Narcolepsy Type 1: Vibrance-1 Phase 2 Results to Be Unveiled at World Sleep 2025

Alkermes is set to present detailed positive results from its Vibrance-1 Phase 2 study of alixorexton, a novel, once-daily oral orexin 2 receptor agonist, in patients with narcolepsy type 1…

Continue Reading Alkermes’ Alixorexton Shows Promise in Narcolepsy Type 1: Vibrance-1 Phase 2 Results to Be Unveiled at World Sleep 2025

Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…

Continue Reading Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy

Excessive daytime sleepiness (EDS) is more than just feeling tired—it can be a debilitating symptom of two distinct neurological disorders: hypersomnia and narcolepsy. While both conditions share the hallmark of…

Continue Reading Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy

Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies

Emerging research highlights the role of genetic predisposition in the development of secondary cardiomyopathies triggered by environmental stressors such as pregnancy, alcohol use, and cancer therapy. Findings published in JAMA…

Continue Reading Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies

“Downton Abbey” Creator Undergoes Transformative Treatment for Tremors

Lord Julian Fellowes, the Oscar-winning creator of Downton Abbey, has undergone a transformative treatment for essential tremor (ET) using Insightec’s magnetic resonance-guided focused ultrasound (MRgFUS) technology. After living with the…

Continue Reading “Downton Abbey” Creator Undergoes Transformative Treatment for Tremors

Experimental Gene Therapy Slows Huntington’s Disease Progression in Landmark Trial

An experimental gene therapy known as AMT-130 has become the first treatment to successfully slow the progression of Huntington’s disease, marking a potential breakthrough in the fight against neurodegenerative disorders.…

Continue Reading Experimental Gene Therapy Slows Huntington’s Disease Progression in Landmark Trial

FDA Signals Flexibility as Lexeo’s Gene Therapy for Rare Disease Advances Toward Faster Approval

Lexeo Therapeutics announced a significant regulatory development this week: the U.S. Food and Drug Administration (FDA) is open to a faster approval pathway for the company’s promising gene therapy, LX2006,…

Continue Reading FDA Signals Flexibility as Lexeo’s Gene Therapy for Rare Disease Advances Toward Faster Approval

Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo have announced promising Phase 3 trial results for Datroway, their investigational antibody-drug conjugate (ADC) targeting triple-negative breast cancer (TNBC). The trial demonstrated that Datroway significantly slowed…

Continue Reading Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer